Northwire Canada EditionMonday, July 13, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Neutral

Canadian Securities Exchange Reports March 2026 Performance Figures

UberDoc Health Technologies Corp.

By The Northwire Desk — AI Analysis Apr 17, 2026 · 13:50 APPT · 0.36 UBERDOC Health Technologies Corp.
Executive Summary
  • The most recent release (April 17, 2026) is a Canadian Securities Exchange (CSE) monthly performance report highlighting trading volume and new listings.
  • UberDoc (APPT) is listed among six new issuers for March 2026, confirming its presence on the exchange but providing no specific operational updates.
  • Previous news (April 14, 2026) details Dr. Paula Muto's appointment to a U.S. Federal Health Advisory Committee (NCVHS), enhancing regulatory credibility.
  • Historical context includes listings on CSE (March 18) and Frankfurt Stock Exchange (March 24) via Reverse Takeover of ROV Investment Partners Corp.
  • Management plans include an OTCQB listing in the U.S. for Q2 2026 to broaden investor access.
Material Impact
  • The most recent CSE report is neutral regarding UberDoc's specific valuation as it aggregates exchange-wide data rather than company-specific fundamentals.
  • The April 14 appointment of Dr. Muto is positive for credibility but does not translate to immediate revenue or earnings, classifying it as incremental rather than material.
  • Stock price declined from $0.40 (March 18) to $0.36 (April 16), indicating the market has not priced in the Frankfurt listing or federal appointment positively yet.
  • Lack of financial statements prevents assessment of whether the reverse takeover carried hidden liabilities or debt obligations.
  • No evidence of capital raises in the provided news suggests current liquidity is sufficient for operations but growth plans may require future financing.
APPT · Price
Company Overview
  • UberDoc operates a two-sided direct-pay marketplace connecting patients with board-certified specialists across 55 U.S. specialties.
  • Platform features include AI-guided symptom matching, transparent upfront pricing, and bypassing insurance/referral barriers.
  • Flagship Project: The digital healthcare platform currently serving over 5,000 physicians in the U.S.
  • Business Model relies on direct patient payments rather than traditional insurance billing to reduce administrative complexity.
Read the original news release →

More from UBERDOC Health Technologies Corp.

Jun 30, 2026 · 08:01

Direct-pay specialist marketplace expands network via Emphera Health partnership to bypass insurance gatekeeping.

M&A / Property May 15, 2026 · 20:01

Founder takes interim CEO role after abrupt exit of public-market shepherd; early-stage credibility in question.

Management Apr 30, 2026 · 08:00

UberDoc AI Partnership Validates Strategy But Liquidity and Revenue Visibility Remain Key Risks

M&A / Property Apr 14, 2026 · 01:01

Direct-pay specialist care marketplace connecting patients with physicians

Management Mar 24, 2026 · 08:31

UberDoc Health Technologies Corp. Announces Listing on the Frankfurt Stock Exchange

Regulatory Mar 18, 2026 · 09:39

UBERDOC Health Technologies Corp. to Begin Trading on the Canadian Securities Exchange Under the Symbol "APPT"

Regulatory